About the Authors
- Josquin Nys
-
Contributed equally to this work with: Josquin Nys, Cristian R. Smulski
Affiliation Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
- Cristian R. Smulski
-
Contributed equally to this work with: Josquin Nys, Cristian R. Smulski
Affiliation Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
- Aubry Tardivel
-
Affiliation Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
- Laure Willen
-
Affiliation Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
- Christine Kowalczyk
-
Affiliation Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
- Olivier Donzé
-
Affiliation Adipogen SA, Epalinges, Switzerland
- Bertrand Huard
-
Affiliations Department of Patho-Immunology, Medical University Centre, Geneva, Switzerland, Division of Hematology, Geneva University Hospital, Geneva, Switzerland
- Henry Hess
-
Affiliation Merck-Serono, Darmstadt, Germany
- Pascal Schneider
-
* E-mail: pascal.schneider@unil.ch
Affiliation Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
Competing Interests
The authors have the following interests. This research was financed in part by a research agreement bewteen Merck-Serono and the University of Lausanne. Henry Hess, who is employed by Merck-Serono provided the essential reagent. Olivier Donzé is employed by Adipogen SA. Atacicept, the drug under investigation in this paper, is being developed by Merck-Serono. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: JN PS. Performed the experiments: JN CRS LW CK AT PS. Analyzed the data: JN CRS PS. Contributed reagents/materials/analysis tools: OD BH HH. Wrote the paper: HH PS.